Clinical trials in Edegem – page 7

516 clinical trials in Edegem, Belgium across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Edegem at a glance

516

clinical trials

Research sites3

Quick filters

516 trials in Edegem

Open in trial search

Endometrial cancer+3

Recruiting

Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

Registered drugNo placebo

Study of ubamatamab alone or with cemiplimab for adults with ovarian, fallopian tube, peritoneal, or endometrial cancer that has come back

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Non-small cell lung cancer stage IIIA+2

Recruiting

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo

Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Dilated cardiomyopathy

Recruiting

A Study of Danicamtiv for Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy to Test if it Improves Heart Function and Exercise Ability

Investigational

A Study of Danicamtiv for Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy to Test if it Improves Heart Function and Exercise Ability

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Danicamtiv
Sponsor:Kardigan Inc.

Contact Research Centre

Cervix carcinoma

Recruiting

A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

Registered drugNo placebo

A Study of Sacituzumab Tirumotecan, Pembrolizumab, and Bevacizumab for Patients with Metastatic Cervical Cancer That Has Spread or Returned

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Non-small cell lung cancer

Recruiting

Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

Registered drugNo placebo

Testing zongertinib compared to standard treatment in patients with early-stage non-small cell lung cancer with HER2 mutations after surgery

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Boehringer Ingelheim Espana S.A.

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

A Study of Amivantamab With Carboplatin and Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Amivantamab
Sponsor:Janssen Cilag International

Contact Research Centre

Pancreatic carcinoma metastatic+1

Recruiting

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug

A Study of BMS-986504 Combined with Nab-Paclitaxel and Gemcitabine for Patients with Untreated Metastatic Pancreatic Cancer with MTAP Gene Deletion

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Gemcitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Diabetes mellitus

Recruiting

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational

Belgium

Participants:0–17 years · 18–64 years
Substances:Teplizumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Endometrial cancer metastatic

Recruiting

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

A Study of Puxitatug Samrotecan Compared to Chemotherapy for Patients with Advanced Endometrial Cancer After Previous Platinum and Immunotherapy Treatment

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:AZD8205
Sponsor:AstraZeneca AB

Contact Research Centre

Hypertrophic cardiomyopathy+1

Recruiting

A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

Investigational

A study testing ninerafaxstat compared to placebo in patients with symptomatic non-obstructive hypertrophic cardiomyopathy

Investigational

Belgium

Participants:18–64 years · 65+ years
Sponsor:Imbria Pharmaceuticals Inc.

Contact Research Centre

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Capivasertib
Sponsor:Relay Therapeutics Inc.

Contact Research Centre

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Edegem

What the registry says about research in the country

01 Infectious Diseases & Immunology

Groundbreaking research focusing on viral infections and vaccine development, including studies for influenza, RSV, and COVID-19. Multiple trials are evaluating immune responses and vaccine efficacy in different age groups.

Vaccine Development
Immune Response Studies
Prevention Strategies

Special attention is given to vulnerable populations, including elderly adults and pregnant women.

02 Liver & Metabolic Disorders

Innovative studies addressing Primary Biliary Cholangitis and Hepatitis D treatments. Research includes evaluation of novel therapeutics and their impact on disease progression.

Liver Disease Management
Clinical Outcomes
Antiviral Therapies

Trials focus on improving patient outcomes and developing targeted treatments.

03 Oncology & Cancer Care

Advanced research in breast cancer and lung cancer treatments, exploring new therapeutic combinations and targeted approaches for better patient outcomes.

Metastatic Disease
Targeted Therapies
Treatment Innovation

Focus on personalized medicine approaches and innovative treatment combinations.

Back to Belgium All countries